Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 250

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 250
---
 deemed relevant. In light of the complexity of those factors, Liminatus’s management as a whole did not consider it practicable to, nor did it attempt to, quantify or otherwise assign relative weights to the specific factors it took into account in reaching their respective decisions. Individual members of Liminatus’s management may have given different weight to different factors.

In particular, the Liminatus management considered the following factors:

•

Liminatus’s operating results and financial performance;

•

the current business conditions;

•

the stage of development of Liminatus’s products and services;

•

the likelihood of achieving a liquidity event, such as an initial public offering, given prevailing market conditions and the nature and history of Liminatus’s business;

•

industry information such as market size and growth;

•

the macroeconomic conditions;

•

the effect of an infusion of working capital on Liminatus’s business and growth strategies; and

<div align='center'>118</div>

TABLE OF CONTENTS

•

the desire of potential customers to deal with a publicly traded Nasdaq-listed Delaware corporation.

### Interests of Certain Persons in the Business Combination
In considering the recommendation of the Iris Board to vote in favor of the Business Combination Proposal, stockholders should be aware that, aside from their interests as stockholders, the Sponsor and certain of Iris’s directors and officers have interests in the Business Combination that are different from or in addition to (and may conflict with) those of other stockholders. Iris’s directors were aware of and considered these interests in evaluating the Business Combination and in recommending to stockholders that they approve the Business Combination. Stockholders should take these interests into account in deciding whether to approve the Business Combination. These interests include:

•

the fact that the Sponsor holds 6,900,000 Founder Shares and 4,177,778 Private Placement Warrants, which would expire worthless if a business combination is not consummated;

•

the fact that, unless Iris consummates the Business Combination, the Sponsor will not receive reimbursement for any out-of-pocket expenses incurred by an affiliate on behalf of Iris ($75,000 of such expenses were incurred that had not been reimbursed as of September 30, 2024) to the extent that such expenses exceed the amount of available proceeds not deposited in the Trust Account;

•

the fact that the Sponsor has made outstanding loans to Iris in the aggregate amount of approximately $1,453,720 as of September 30, 2024, which amount Iris will be unable to repay to the Sponsor to the extent